The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Sumitomo Dainippon Flip-Plops on Sales Force Cutback as It Ramps Up Diabetes Push
After a DPP-4 copromotion pact inked with Novartis Pharma, Sumitomo Dainippon Pharma is making a U-turn with its previous plan to pare down its sales force and is now set to even hire more contract reps in a bid to…
To read the full story
Related Article
- Sumitomo Dainippon to Solely Promote Novartis Diabetes Meds from January
November 20, 2019
BUSINESS
- Takeda Taps Halozyme’s Delivery Tech to Develop New Entyvio SC Formulation
January 13, 2026
- Japan Heart Failure Drug Market Seen 1.5-Fold Growth by 2030: Fuji Keizai
January 13, 2026
- Daito Secures China Approval for EquMet Generic
January 13, 2026
- Japan Ethical Drug Sales Edge Up 0.4% in November: Crecon
January 13, 2026
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…